Healthcare Sales & Marketing Network News: Namenda XR

Searching News Database: Namenda XR

HSMN NewsFeed - 21 Feb 2018
Amneal Introduces Memantine Hydrochloride Extended-Release Capsules, Generic for Namenda XR(R)
Biopharmaceuticals Generics Product Launch

HSMN NewsFeed - 29 Sep 2016
Allergan Issues Statement on Namenda XR Patent Litigation Following Announcement of ANDA Approvals
Biopharmaceuticals Generics FDA Litigation

HSMN NewsFeed - 31 Aug 2016
Allergan and Adamas Announce Settlement with Amneal Related to NAMZARIC(R) Patent Litigation
Biopharmaceuticals Generics Litigation

HSMN NewsFeed - 18 May 2015
Actavis Launches NAMZARIC(TM) (memantine hydrochloride extended-release and donepezil hydrochloride), a Fixed-Dose Combination Therapy for the Treatment of Moderate to Severe Alzheimer's Disease
Biopharmaceuticals Neurology Product Launch

HSMN NewsFeed - 24 Dec 2014
Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride
Biopharmaceuticals Neurology FDA

HSMN NewsFeed - 2 Feb 2014
Forest Laboratories, Inc. Files Lawsuit Against Several Companies for Infringement of NAMENDA XR(R) Patents
Biopharmaceuticals Neurology Generics Litigation

HSMN NewsFeed - 14 Nov 2012
Forest Laboratories and Adamas Pharmaceuticals Enter into Licensing Agreement for the Development and Commercialization of a Fixed Dosed Combination of Namenda XR(R) and Donepezil for Alzheimer’s Disease
Biopharmaceuticals Neurology Licensing

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.